266 related articles for article (PubMed ID: 28669065)
1. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
Mendivil AA; Rettenmaier MA; Abaid LN; Brown JV; Mori KM; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2017 Aug; 80(2):405-410. PubMed ID: 28669065
[TBL] [Abstract][Full Text] [Related]
2. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Abaid LN; Brown Iii JV; Wilcox AM; Goldstein BH
Int J Hyperthermia; 2015 Feb; 31(1):8-14. PubMed ID: 25559985
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
Rettenmaier MA; Micha JP; Bohart R; Goldstein BH
Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():101-105. PubMed ID: 31778904
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Gray CM; Chapman AP; Stone MK; Tinnerman EJ; Goldstein BH
Int J Hyperthermia; 2015 Jun; 31(4):396-402. PubMed ID: 25707816
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
Carrabin N; Mithieux F; Meeus P; Trédan O; Guastalla JP; Bachelot T; Labidi SI; Treilleux I; Rivoire M; Ray-Coquard I
Bull Cancer; 2010 Apr; 97(4):E23-32. PubMed ID: 20202920
[TBL] [Abstract][Full Text] [Related]
7. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Chiva LM; Gonzalez-Martin A
Gynecol Oncol; 2015 Jan; 136(1):130-5. PubMed ID: 25434634
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
[TBL] [Abstract][Full Text] [Related]
9. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
10. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study.
Le Brun JF; Campion L; Berton-Rigaud D; Lorimier G; Marchal F; Ferron G; Oger AS; Dravet F; Jaffre I; Classe JM
Ann Surg Oncol; 2014 Oct; 21(11):3621-7. PubMed ID: 24819120
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
14. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
Kim JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Lee KH; Lee SH; Kim SJ
J Surg Oncol; 2010 Feb; 101(2):149-55. PubMed ID: 20035540
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
[TBL] [Abstract][Full Text] [Related]
16. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Abaid LN; Brown JV; Micha JP; Wilcox AM; Goldstein BH
Arch Gynecol Obstet; 2015 Jun; 291(6):1381-6. PubMed ID: 25516177
[TBL] [Abstract][Full Text] [Related]
18. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
[TBL] [Abstract][Full Text] [Related]
19. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
20. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
